Medline (MDLN)

Medline (MDLN-Q) has shown promising performance since its IPO, experiencing a significant rise of 39.4% since its debut. The stock has closed 41% above its initial offering price, indicating robust demand from investors. The company reported a solid 9.8% growth in net sales and an impressive adjusted EBITDA margin of 12.9% in the first nine months of 2025. Despite the strong performance, investors should be cautious as existing shareholders retain 80% of the voting power, which may limit influence for new buyers. At a price-to-earnings ratio of approximately 45x, the valuation appears steep given the company’s low double-digit growth, suggesting potential risks for future investors if they buy at current levels.